|Bid||0.0800 x N/A|
|Ask||0.0950 x N/A|
|Day's Range||0.0850 - 0.0900|
|52 Week Range||0.0750 - 0.1600|
|Beta (5Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr. 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, BC / ACCESSWIRE /September 7, 2021 / Pascal Biosciences Inc. ("Pascal") (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF), announced today the appointment of Rob Gietl as Chief Executive Officer and President, and he will also have a position on the Board of Directors.
VANCOUVER, BC / ACCESSWIRE / June 16, 2021 / Pascal Biosciences Inc. ("Pascal") (TSXV:PAS) (OTC PINK:PSCBF) (FSE:6PB), announced today the appointment of Hardy Forzley as Chief Financial Officer.
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Pascal Biosciences (TSXV: PAS) (OTC Pink: PSCBF) (FSE: 6PB), a biotechnology company targeting innovative therapies for serious diseases, including COVID-19, has been awarded a grant from the National Cancer Institute of the US National Institutes of Health. This two-year grant of US$343,750 will fund development of Pascal's antibody drug for Acute Lymphoblastic Leukemia or "ALL".For more information, please view the InvestmentPitch